title: ACP Journal Club. Review: rosiglitazone increases risk for cardiovascular outcomes and mortality compared with pioglitazone in type 2 diabetes.
authors.affiliation: University of California, San Francisco, School of Medicine, Fresno, California, USA.
authors.forename: Prakash
authors.initials: P
authors.lastname: Deedwania